Operating CF
$17.89B
Capex
−$3.77B
Free Cash Flow
$14.12B
FCF Margin
+78.9%
Cash flow waterfall for Merck & Co. (MRK) — TTM through Q1 2026
Free cash flow: $14.12B
Cash flow breakdown for Merck & Co. (MRK) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $17.89B | $17.89B |
| Capital Expenditure | −$3.77B | $14.12B |
| Free Cash Flow | $14.12B | $14.12B |
| Acquisitions | −$18.82B | −$4.71B |
| Other Investing | $132.00M | −$4.57B |
| Share Buybacks | −$981.00M | −$5.55B |
| Dividends Paid | −$8.23B | −$13.79B |
| Net Debt Change | $13.80B | $12.00M |
| Other Financing | −$3.73B | −$3.72B |
| Forex Effect | $444.00M | −$3.28B |
| Net Cash Decrease | −$3.28B | −$3.28B |
- Operating Cash Flow$17.89B
- Capital Expenditure−$3.77B
- Free Cash Flow$14.12B
- Acquisitions−$18.82B
- Other Investing$132.00M
- Share Buybacks−$981.00M
- Dividends Paid−$8.23B
- Net Debt Change$13.80B
- Other Financing−$3.73B
- Forex Effect$444.00M
- Net Cash Decrease−$3.28B
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Merck & Co. (MRK) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement